We are live on
!
Find out more
VEA
Virtus ETF Advisers Portfolio holdings
AUM
$215M
1-Year Est. Return
53.68%
This Fund
S&P 500
This Quarter
Est. Return
+12.86%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$158M
AUM Growth
-$7.14M
(-4.3%)
Cap. Flow
-$21.7M
Cap. Flow
% of AUM
-13.81%
Top 10 Holdings %
Top 10 Hldgs %
5.64%
Holding
474
New
40
Increased
153
Reduced
231
Closed
49
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Expedia Group
EXPE
|
+$752K |
| 2 |
Gartner
IT
|
+$681K |
| 3 |
Trane Technologies
TT
|
+$681K |
| 4 |
Eaton
ETN
|
+$660K |
| 5 |
Prologis
PLD
|
+$658K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$854K |
| 2 |
Arthur J. Gallagher & Co
AJG
|
+$778K |
| 3 |
IDEX
IEX
|
+$731K |
| 4 |
Tesla
TSLA
|
+$719K |
| 5 |
Yum China
YUMC
|
+$714K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 22.36% |
| 2 | Technology | 15.51% |
| 3 | Financials | 14.54% |
| 4 | Industrials | 9.65% |
| 5 | Energy | 8.22% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
SAGE
201
DELISTED
Sage Therapeutics
SAGE
| $333K | 0.21% |
15,380
+10,140
| +194% | +$201K |
|
202
Theravance Biopharma
TBPH
$874M
| $333K | 0.21% |
29,628
+396
| +1% | +$3.99K |
|
203
Sarepta Therapeutics
SRPT
$1.68B
| $333K | 0.21% |
3,451
+1,117
| +48% | +$107K |
|
|
DCPH
204
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $332K | 0.21% |
20,606
-854
| -4% | -$10.9K |
|
205
Ionis Pharmaceuticals
IONS
$9.25B
| $331K | 0.21% |
6,548
-909
| -12% | -$43.5K |
|
206
BioNTech
BNTX
$23B
| $331K | 0.21% |
3,138
+398
| +15% | +$40.1K |
|
207
Biogen
BIIB
$29.5B
| $329K | 0.21% |
1,272
+256
| +25% | +$62.9K |
|
208
Roivant Sciences
ROIV
$25B
| $329K | 0.21% |
29,308
-2,030
| -6% | -$19.8K |
|
209
Ironwood Pharmaceuticals
IRWD
$644M
| $326K | 0.21% |
28,489
+951
| +3% | +$9.41K |
|
210
Amylyx Pharmaceuticals
AMLX
$2.17B
| $326K | 0.21% |
22,130
+9,907
| +81% | +$152K |
|
211
PTC Therapeutics
PTCT
$6.29B
| $326K | 0.21% |
11,819
+4,744
| +67% | +$108K |
|
212
Aurinia Pharmaceuticals
AUPH
$1.96B
| $325K | 0.21% |
36,124
+5,267
| +17% | +$43.4K |
|
213
CRISPR Therapeutics
CRSP
$4.6B
| $324K | 0.21% |
5,183
+3,502
| +208% | +$194K |
|
214
Gilead Sciences
GILD
$162B
| $323K | 0.21% |
3,989
+48
| +1% | +$3.73K |
|
215
BioMarin Pharmaceuticals
BMRN
$11.6B
| $322K | 0.2% |
3,342
+121
| +4% | +$10.7K |
|
216
Incyte
INCY
$23.7B
| $321K | 0.2% |
5,110
+159
| +3% | +$8.99K |
|
217
Legend Biotech
LEGN
$3.73B
| $320K | 0.2% |
5,314
+905
| +21% | +$57.4K |
|
|
ONC
218
BeOne Medicines Ltd
ONC
$33.8B
| $314K | 0.2% |
1,739
+280
| +19% | +$50.7K |
|
219
Agios Pharmaceuticals
AGIO
$2.2B
| $313K | 0.2% |
14,036
+2,213
| +19% | +$49.6K |
|
220
Harmony Biosciences
HRMY
$2.08B
| $312K | 0.2% |
9,657
+1,147
| +13% | +$32K |
|
221
Gladstone Investment Corp
GAIN
$648M
| $311K | 0.2% |
21,997
-15,634
| -42% | -$216K |
|
222
Halozyme
HALO
$9.66B
| $306K | 0.19% |
8,269
-962
| -10% | -$36.2K |
|
223
BioCryst Pharmaceuticals
BCRX
$2.43B
| $304K | 0.19% |
50,731
+12,410
| +32% | +$71.9K |
|
224
Invesco Quality Municipal Securities
IQI
$526M
| $303K | 0.19% |
31,868
-13,249
| -29% | -$117K |
|
225
OFS Capital
OFS
$46M
| $297K | 0.19% |
25,347
-8,197
| -24% | -$88.4K |
|
Similar funds
NCM
SSA
LIWM
VFG
IAM
1M
GC
ALS
Virtus ETF Advisers's Q4 2023 Portfolio in Review
As of Q4 2023, Virtus ETF Advisers held 474 positions worth $158M, down 4.3% from $165M the previous quarter. Its ten largest holdings account for 5.6% of the portfolio.
Virtus ETF Advisers withdrew a net $21.7M in Q4 2023, closing 49 positions and reducing 231 holdings. Its most notable exit was Horizon Therapeutics Public Limited Company Ordinary Shares, an estimated $854K position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 22% of assets, up from 19% a quarter earlier, followed by Technology and Financials.
Against the trend, Virtus ETF Advisers opened a new position in Expedia Group worth $932K.
- Virtus ETF Advisers's largest Q4 2023 buy was Expedia Group: 6,139 shares worth $932K.
- Virtus ETF Advisers added most to Pioneer Natural Resource Co. in Q4 2023, an estimated $535K increase.
- Virtus ETF Advisers's biggest Q4 2023 reduction was VICI Properties, cutting an estimated $659K.
- Virtus ETF Advisers fully exited Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2023, selling an estimated $854K.
- Virtus ETF Advisers's ten largest holdings make up 5.6% of its $158M portfolio in Q4 2023.
- Virtus ETF Advisers opened 40 new positions and closed 49 in Q4 2023.
- Virtus ETF Advisers's portfolio value fell 4.3% quarter-over-quarter to $158M.
Based on Virtus ETF Advisers's 13F filing for Q4 2023, filed 15 Feb 2024.